- Coordinator
- Fundacio Institut De Recerca Contra La Leucemia Josep Carreras, Spain
- Runs
- 1 November 2026 to 31 October 2031
- Status
- Running
- EU funding
- €3.5m
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101268231
What the project is doing
In the project's own words, from its summary on CORDIS.
Despite recent advances, we still lack a coherent framework explaining how genetic lesions, aberrant cell fate decisions and host factors intersect to drive immunological neoplasms (lymphoma). We have uncovered an entirely new dimension: gender bias as a fundamental driver of lymphoma evolution. Our data show that a newly discovered type of lymphoma called BN2-DLBCL, defined by SPEN and NOTCH2 truncations, is specifically highly aggressive in women and rooted in the biology of aged/autoimmune B cells (AiBCs); cells classically linked to autoimmunity.
This suggests a central role for female gender effects where immune dysfunction, chronic inflammation, and failed X-chromosome inactivation (XCI) converge. We hypothesize that SPEN loss destabilizes XCI, unleashing bi-allelic expression of X-encoded TLR7/IRAK1 and hyperactive inflammatory signaling; NOTCH2 mutations reroute these signals into AiBC fate, creating lymphoma precursors that expand clonally, exhaust T cells, and reshape immune microenvironments.
The result is a uniquely female-biased malignant trajectory, overturning conventional lymphoma paradigms. With X-SeLECT (X-chromosome role in SEx-dependent Lymphoma Evolution and Clonal Trajectories) we will systematically dissect this biology. Using single-cell multi-omics, spatial proteogenomics, real-time dynamics (3-photon microscopy), and lineage tracing, we will reconstruct the stepwise clonal evolution of AiBCs into BN2-DLBCL and define the gender-specific immune circuits that sustain them.
Finally, we will exploit these insights to uncover sex-specific vulnerabilities, testing how TLR/IRAK blockade, statins, and immune checkpoint synergy can dismantle these malignant networks. This project will deliver a paradigm shift: establishing AiBCs as the first bona fide lymphoma-initiating and repopulating cells, demonstrating that gender and X-linked immunity are central to cancer biology, and charting the way toward precision, sex-informed therapies in lymphoma.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fundacio Institut De Recerca Contra La Leucemia Josep Carreras | Badalona | Spain | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS